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1991-7902/Copyrightª 2015, AssociatioAbstract Background/purpose: In this study, we evaluated the effectiveness of oral uracil
etegafur (UFUR) as a postoperative adjuvant treatment for patients with advanced oral squa-
mous cell carcinoma (OSCC).
Materials and methods: The study cohort consisted 80 patients with advance cancer treated
between January 2003 and December 2007. Half of the patients received oral UFUR as postop-
erativemetronomic adjuvant chemotherapy, while the other half received no treatment. No pa-
tients received postoperative radiotherapy or other systemic chemotherapy. Disease-free
survival and toxicity were evaluated in these two groups. Twenty-two patients were assessed
pre- and postoperatively for viable circulating endothelial progenitor cells using flow cytometry.
Results: The disease-free survival rates at 4 years were 84.6% with oral UFUR treatment and
60.9% without UFUR therapy (P Z 0.02). The toxicity and disease progression profiles did not
differ significantly between the two groups, but viable circulating endothelial progenitor cell
counts decreased after the administration of oral UFUR. Advanced OSCC patients who received
oral UFUR had a better prognosis than those who did not.
Conclusion: Oral UFUR is a promising postoperative metronomic adjuvant chemotherapy
regimen for advanced OSCC.
Copyrightª 2015, Association for Dental Sciences of the Republic of China. Published by Elsevier
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Oral UFUR in advanced oral cancer therapy 409IntroductionOral squamous cell carcinoma (OSCC) is the fourth major
cause of mortality among men in Taiwan, and its incidence
continues to rise annually.1 According to analyses con-
ducted by the Department of Oral and Maxillofacial Surgery
of Mackay Memorial Hospital, Taipei, Taiwan the post-
operative overall 5-year survival rate for OSCC is 65.45%,
and > 85% of patients with stage I and II OSCC survive for at
least 5 years after the treatment.2 However, the survival
rate was found to be < 50% in stage IV patients. Survival
rates are particularly low in patients with cervical lymph
node metastasis.
Most patients with newly diagnosed OSCC are already in a
late stage of disease, and large tumors are associated with a
higher local recurrence rate. Field cancerization has been
proposed as the main cause of recurrence and second pri-
mary cancers among patients who have undergone advanced
resection.3 Postoperative adjuvant treatment involves
eradication of these microtumors to prevent them from
recurring locally. The National Comprehensive Cancer
Network (NCCN) guideline V2 2014 states that surgery is the
preferable treatment for oral cavity cancer (http://www.
nccn.org/professionals/physician_gls/f_guidelines.asp). Con
sequently, radiotherapy, chemotherapy, or a combination of
both is usually administered after surgery. However, some
patients refuse, and older patients ( 70 years) may not be
able to tolerate, postoperative radiotherapy; in these cases,
postoperative chemotherapy may improve treatment out-
comes. Several randomized clinical trials on gastric, lung,
colon, and breast cancers have indicated that postoperative
adjuvant treatments can significantly improve survival
rates.4 Other studies have shown that intravenous post-
operative chemotherapy with cisplatin combined with
5-fluorouracil (5-FU) improved the survival of patients with
advanced stage cancers or cervical metastasis.5 However, it
has been shown that the recommended doses often have
severe side effects and can even cause sudden death.5
Therefore, orally administered low-dose chemotherapy
agents such as fluoropyrimidines, uraciletegafur (UFUR),
capecitabine, and fluoropyrimidines have been recently
developed. Chemotherapeutic agents are administered
orally, both for convenience and to increase patient
compliance. Advantages of oral chemotherapeutic agents
have been shown to include a reduction in acute toxicities
such as high grade myelosuppression, vomiting, nausea, and
mucositis,6 and sometimes surprisingly good activity against
drug-resistant tumors.7 However, a disadvantage of oral
chemotherapy is that patients cannot be monitored closely
and therefore may continue with cytotoxic therapy without
appropriate medical support. As a result, communication
with patients regarding drug-related issues and intensive
outpatient follow-up are of considerable importance.8 Oral
administration is generally safer than the intravenous de-
livery of chemotherapeutic-agents. Several studies
assessed the use of oral chemotherapeutic agents in the
postoperative adjuvant treatment of different malig-
nancies including lung, breast, colon, and rectal can-
cer.9e11 One of these was a prospective randomized study
of postoperative oral chemotherapy with levamisole and
UFUR for the treatment of head and neck cancer. A trendtowards better distant control in postoperative oral
chemotherapy patients was observed, and toxic side ef-
fects were minimal in the study group.12 In this study, we
assessed the use of oral UFUR only as a metronomic
chemotherapy in advanced OSCC patients who refused
postoperative adjuvant radiotherapy, and analyzed the
survival rate and adverse effects in these patients.
Materials and methods
The study cohort comprised patients treated in the
Department of Oral and Maxillofacial Surgery, Mackay Me-
morial Hospital, between January 2003 and December 2007
who were diagnosed with OSCC by histopathology. Patients
with a previous history of malignancy, or who were immu-
nocompromised, were excluded from analysis. The study
patients received their initial treatments in our hospital and
had not undergone surgical resection, radiotherapy, or
chemotherapy in other hospitals. Computed tomography,
99Tc whole body bone scans, chest radiograms, and whole-
abdomen echograms were used for clinical staging. The
study cohort included 80 patients with advanced OSCC who
had undergone tumor resection and cervical lymph node
dissection. The final diagnosis was dependent on the histo-
pathological results and the AJCC (7th edition) tumor clas-
sification. The inclusion criterion was primary T3eT4 tumors
without cervical lymphatic metastasis or primary T2-T3 tu-
mors with N1 cervical lymph node metastasis. Patients who
had positive surgical margin or extracapsular lymph node
spread were excluded from the study. All of the patients had
refused postoperative radiotherapy and were notified of the
risks and side effects associated with chemotherapy.
The patients were randomly divided into two groups as
follows: 40 patients received orally administered UFUR 4
weeks after surgery as an adjuvant metronomic chemo-
therapy at a dose of 150 mg/m2/d, twice daily for 12
months. During the follow-up period visits were conducted
on a regular basis, hematology laboratory tests and serum
profile tests were performed every 3rd month, and medical
imaging including computed tomography, chest radiog-
raphy, whole abdomen echography, and 99Tc whole body
bone scans were conducted every 4 months to exclude
locoregional recurrence or distant metastasis. In addition,
22 patients who received oral UFUR were randomly
selected to have their blood tested to determine the
number of circulating endothelial cells (CECs) and circu-
lating endothelial progenitor (CEP) cells both prior to and
after chemotherapy. All the patients signed the informed
consent form after approval by the Institutional Review
Board (Mackay Memorial Hospital). Statistical analyses were
performed to determine the significance of differences in
overall survival rates, toxicity and the number of CEP cells
between the two groups.
CECs and CEP cell evaluation by flow cytometry
CEC and CEP cell counts were evaluated in all patients as
previously described. In brief, fresh blood samples were
immunostained for anti-CD45 (to exclude hematopoietic
cells), anti-CD31 (an endothelial marker; BD Biosciences),
anti-CD133 (a progenitor cell marker; MACS), anti-CD146
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Figure 1 KaplaneMeier survival curves for patients who
received postoperative oral uraciletegafur (UFUR) therapy
versus the control group. The disease-free survival rates at 48
months were 85.6% for the oral UFUR group and 75.9% for the
control group. The P values were calculated using the stratified
log-rank test.
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marker 7-aminoactinomycin D (Merck). Red blood cells
were lysed in red cell lysis buffer and viable and apoptotic
CECs and CEP cells were analyzed by fluorescence-
activated cell sorting (BD Biosciences). CECs were defined
as being negative for the hematopoietic marker CD45 and
the progenitor marker CD133, and positive for the endo-
thelial markers CD146 and CD31. CEP cells were identified
by the expression of CD133.13
Statistical analysis
The Student t test, Chi-squared test, and Fisher’s exact test
were used to compare the various clinical variables be-
tween the two groups. Disease-free survival rates were
analyzed using the KaplaneMeier method, and the Man-
neWhitney U pairs test was employed to analyze changes in
the number of CEP cells prior to and after therapy. The Cox
proportional hazards regression model was used to identify
statistically significant variables related to survival. Sta-
tistical significance was defined as P < 0.05.
Results
The clinical data of these patients is summarized in Table 1.
Patients who received UFUR treatment had a survival rate
of 84.6%, while those who did not had a survival rate of
60.9%. KaplaneMeier analysis indicated that patients
treated with UFUR had longer progression-free survival
(Fig. 1). Locoregional recurrence accounted for a large
proportion of treatment failure (Table 1). Of the patients
receiving orally administered UFUR, 2.5% experienced
neutropenia, 2.5% had anemia, 2.5% had nausea and vom-
iting, and 5% had an erythematous skin rash; the fre-
quencies of these events did not differ significantly from
those in the control group (Table 2). Cox regression models
indicated that oral UFUR was an independent risk factor for
(Table 3). Eighteen of the 22 patients receiving orallyTable 1 Clinical data from patients treated with or
without oral uraciletegafur (UFUR).
Surgery þ
Oral UFUR
Surgery
only
P
Sex (male:female) 38:2 37:3 > 0.99a
Age (y) 51.2 52.7 0.1b
T3N0M0 22 23
T2-3N1M0 5 6
T4N0M0 13 11 0.8c
Well-differentiated cells 25 23
Moderately differentiated cells 12 14
Poorly differentiated cells 3 3 0.8c
Lymphovascular permeation 4 4 > 0.99
Perineural invasion 5 6 > 0.99
Died
Locoregional recurrence 4 10
Distant metastasis 2 5 0.03a
a Fisher’s test.
b t test.
c Chi-square test.administered UFUR showed a reduction in the number of
viable CEP cells (80.9%; Fig. 2), and there was a statistically
significant decrease in the number of viable CEP cells after
treatment (Fig. 3). Of the three patients whose viable CEPs
did not reduce after UFUR treatment, two died due to the
locoregional failure, and the other survived without
recurrence. However, these differences were not statisti-
cally significant, probably due to the small number of
cases.Discussion
5-FU was first synthesized by Heidelberger et al.14 The
anticancer mechanism of 5-FU lies in its inhibition of thy-
midylate synthase, reducing the synthesis of thymidylate
and subsequently, the synthesis of DNA and RNA. It has
become the most commonly used anticancer agent, and is
widely administered to treat gastric, colorectal, pancre-
atic, and breast cancer.6e8 The absorption of orally
administered 5-FU is very poor because it is rapidly
degraded by dihydropyrimidine dehydrogenase (DPD) in the
intestine. Therefore, in order to maintain concentrations of
5-FU in the blood, continuous intravenous infusion is used.
Orally administered agents with better absorption have
been developed. Tegafur is the precursor of 5-FU, and itsTable 2 Adverse effects of oral uraciletegafur (UFUR)
administration (all cases were Grade 1). Toxicity was graded
according to the criteria of the Taiwan Society of Clinical
Oncology.
Adverse effects Surgery þ Oral UFUR Surgery only
Cases (n) % Case (n) %
Neutropenia 1 2.5 0 0
Anemia 1 2.5 0 0
Raised AST 0 0 0 0
Nausea/vomiting 1 2.5 0 0
Skin rash 2 5 0 0
AST Zaspartate aminotransferase.
Table 3 Cox regression model to compare survival be-
tween patients treated using oral uraciletegafur (UFUR)
and surgery or surgery alone.
HR 95% CI P
Surgery only 1.00
Surgery þ Oral UFUR 0.78 0.57e0.98 0.04
CI Z confidence interval; HR Z hazard ratio.
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Figure 3 Serum levels of viable circulating endothelial pro-
genitor cells before and after uraciletegafur treatment of oral
squamous cell carcinoma patients before and after dot plots of
cell numbers between preoperative and postoperative sample
pairs. Lines connect the values from the same individual.
ManneWhitney U pairs test.
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5-FU levels. It is slowly converted to 5-FU through the P-450
enzyme system and thymidine phosphorylase in tumor tis-
sues.6 Uracil itself is a component of nucleic acids, and has
neither pharmaceutical efficacy nor toxicity. It is a natural
pyrimidine that must be metabolized by DPD; it can thus
compete with 5-FU for DPD, thereby slowing down its
degradation and extending its effective duration and
availability.6,15 A number of clinical trials have shown that
orally administered UFUR adjuvant chemotherapy is
effective.15 Some reports compared the results of orally
administered UFUR/leucovorin combination with intrave-
nously injected 5-FU/leucovorin and concluded that theyFigure 2 Flow cytometric dot plot panels show representative p
mature circulating endothelial cells (CECs), both apoptotic and viab
analysis gate used to exclude platelets and debris and (A2) the g
antigen versus side scatter (SSC). (B) Dot plots to determine the pro
restricted to a CD31þ/CD133 population, used to evaluate matur
and viable CEC subsets.had similar efficacies, although oral administration resulted
in fewer side effects.16 In this study, we administered oral
UFUR as a postoperative adjuvant treatment for OSCC. The
disease-free survival rate was w9% higher than that ofictures for each gating strategy used for the identification of
le, and circulating endothelial progenitor (CEP) cells. (A1) The
ate used to exclude hematopoietic cells expressing the CD45
portion of apoptotic and viable CECs), and CEP cells. (B1) Gate
e CECs. (B2) Expression of antigens used to evaluate apoptotic
412 J.-S. Lin et aluntreated patients, indicating that 5-FU can control OSCC
effectively via oral administration.
Metronomic chemotherapy is the continuous adminis-
tration of pharmaceutical agents at low doses but at short,
regular intervals (daily, several times/wk, or weekly) in
order to maintain their blood concentrations and to repress
tumor angiogenesis. The dosage is usually much lower than
the conventional maximum tolerable dose, reducing the
need to suspend treatment compared to conventional
chemotherapy. Metronomic chemotherapy does not attack
tumors; rather, it blocks the formation of new tumor-
derived blood vessels to cut off the supply of nutrients
required for tumor growth.17 Patil et al.18 reported the
effectiveness and toxicity of a metronomic chemotherapy
regimen with a palliative intent in head and neck cancers.
They found only minimal toxicity, and that the median
progression-free and overall survival were 153 days and 186
days, respectively. They concluded that metronomic
chemotherapy is well tolerated and has a potential role in
the palliative treatment of head and neck cancer. Metro-
nomic chemotherapy is not only less toxic but also main-
tains long-term cytotoxicity against cancer cells in the
blood, thereby avoiding the sanctuary effect arising from
the uneven concentrations of agents, reducing drug resis-
tance and side effects.18
Browder et al7 reported that low-dose injection of
cyclophosphamide inhibits tumor growth in mice, causing
endothelial apoptosis and reduced angiogenesis, and Bocci
et al19 found that metronomic chemotherapy boosts could
knock out THBS1 and obstruct angiogenesis. Kieran et al20
reported that when 20 patients who were nonresponsive
to surgery, radiotherapy, and conventional chemotherapy
were orally administered low doses of thalidomide, cele-
coxib, and cyclophosphamide for 6 months, a significant
increase in disease-free survival rates was observed after
2.5 years. Several clinical trials have confirmed the effec-
tiveness of metronomic chemotherapy, in malignancies,
such as breast, lung, gastric, and colon cancer.21
The present study applies the concepts of metronomic
chemotherapy to the oral administration of UFUR to OSCC
patients. The dose of tegafur used in conventional oral
UFUR treatment is 300 mg/m2/d. Based on a study by
Kerbel et al,8 we used 150 mg of tegafur twice daily for 1
year.20 This dose was relatively low compared to that used
in conventional treatment. After long follow-up period, the
disease-free survival rate was significantly higher than that
of control group. The results suggest that low dose metro-
nomic chemotherapy is an effective adjuvant therapy in
treating oral cancer.
The side effects of long-term administration of oral
UFUR are similar to those seen with intravenous injection of
5-FU, and are related to the daily dose and duration of
treatment. The most common side effects are gastroin-
testinal disorders such as nausea, vomiting, and diarrhea,
bone marrow inhibition leading to leucopenia, thrombocy-
topenia, and anemia, and liver damage leading to acute
hepatitis, pigmentation, and red and dried scars on the
hands (handefoot syndrome). Cautious and regular moni-
toring of the blood, liver, and kidneys is required. It has
been reported that orally administered UFUR and UFUR
combined with leucovorin causes fewer side effects.4 In this
study, we observed that only one patient developedneutropenia, one patient had anemia, one patient experi-
enced nausea and vomiting, and two patients developed
cutaneous eruptions. The fraction of patients experiencing
side effects did not differ significantly between the UFUR
treated and control groups. In comparison to previous
studies using conventional chemotherapy with intravenous
5-FU, there seemed to be far fewer side effects in our
study. Thus, oral UFUR appears to be better tolerated.
Under normal circumstances, angiogenesis occurs during
wound repair and the menstruation; pathological angio-
genesis occurs in some disease processes, including diabetic
retinopathy, degenerative arthritis, and cancer.22 Hladovec
and Rossman first found increased numbers of CECs and
endothelial progenitor cells (EPCs) in cancer patients.23
EPCs are a subgroup of vascular progenitor cells found in
bone marrow and its blood supply. They are capable of
differentiating into vascular endothelial cells and are rarely
found in healthy people. EPCs enter the bloodstream from
the bone marrow, differentiation into vascular endothelial
cells, and facilitate tumor angiogenesis.24 In animal ex-
periments, Duda et al25 found that bone-marrow derived
CEP cells were involved in tumor angiogenesis, and Shaked
et al26 also found that CEP cells were rapidly mobilized by
agents that disrupt the vasculature and developed into
tumor rims in mouse models. Tumor rims shrink and blood
flow is reduced after the administration of agents that
inhibit CEP cells, proving that they play an important role in
angiogenesis. Thus, the presence of CEP cells and EPCs can
serve as indicators to assess and predict the effectiveness
of chemotherapy,27 and quantifying CEP cells is one of the
methods used to assess the effectiveness of treatments.28
There was a significant reduction in CEPs in our patients
after the oral administration of UFUR, which may explain
why metronomic chemotherapy was effective. It also has
antiangiogenic effects when used at low doses, as it attacks
the endothelial cells of tumor blood vessels. However,
three of the patients in this study did not show diminished
CEPs cell levels after oral UFUR. In late-stage cancer pa-
tients, multiple confounders accompanying the disease
might change the number of CEP cells, including inflam-
mation29 and an individual’s immune response to chemo-
therapy.30 That increase had already started a few hours to
several months after chemotherapy.27 The relatively small
number of patients in this study represents an important
limitation, and hence the present findings need to be
confirmed in a study with more OSCC patients.
In conclusion, the results of this study demonstrate that
low-dose orally administered UFUR is beneficial to patients
with advanced OSCC who have undergone resection. In
addition to having lower toxicity, low-dose orally adminis-
tered UFUR results in higher survival rates among OSCC
patients. The number of viable CEP cells is reduced after
treatment, indicating an inhibition of endothelial cell
growth and angiogenesis. We therefore conclude that orally
administered UFUR can serve as an effective postoperative
adjuvant therapy for high-risk and advanced OSCC patients.Conflicts of interest
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